Table 2 Outcomes of included studies.
First author (year) | Treatment | GOS Score at 3 Months | GOS Scores at 6 Months | GOS Scores at 12 Months | ICP level after Intervention (mm Hg) | Overall Mortality, n (%) | LOH (d) | LO-ICU (d) | N of patients with one or more complications |
|---|---|---|---|---|---|---|---|---|---|
Taylor14 | DC | NA | Favorable: 7 (53.8%); Unfavorable: 6 (46.2%) | NA | 17.4 ± 3.4 (range: 11–25) | 3 (23.1) | 26.8 (range: 13.8–73.3) | 9.6 (range: 1.7–31.2) | NA |
Medical therapy | NA | Favorable: 2 (14.3%); Unfavorable: 12 (85.7%) | NA | 21.9 ± 8.5 (range: 11–44) | 6 (42.9) | 47.7 (range: 21.9–73.1) | 12.8 (range: 1.0–14.8) | ||
Josan16 | DC | NA | NA | Favorable: 6 (100%); Unfavorable: 0 (0) | 12.33 ± 2.73 | 0 | NA | NA | NA |
Medical therapy | NA | NA | Favorable: 3 (50%); Unfavorable: 3 (50%) | NA | 2 (33.3) | NA | NA | ||
Olivecrona15 | DC | NA | Favorable: 15 (71.4%); Unfavorable: 6 (28.6%) | NA | 13.1 ± 2.1 | NA | NA | NA | NA |
Medical therapy | NA | Favorable: 43 (60.6); Unfavorable: 28 (39.4) | NA | NA | NA | NA | NA | ||
Rubiano18 | DC | NA | Favorable: 7 (44%); Unfavorable: 9 (56%) | NA | NA | 4 (25) | 23.4 (range: 5–57) | 9.4 (range: 5–20) | NA |
Medical therapy | NA | Favorable: 0 (0%); Unfavorable: 20 (100%) | NA | NA | 13 (65) | 10.1 (range: 2–31) | 5.9 (range: 2–13) | ||
Qiu6 | DC | NA | Favorable: 21 (57%); Unfavorable: 16 (43%) | NA | 24 h:15.19 ± 2.18; 48 h: 16.53 ± 1.53; 72 h: 15.98 ± 2.24; 96 h: 13.52 ± 2.33 | 10 (27) | NA | NA | NA |
Medical therapy | NA | Favorable: 12 (32%); Unfavorable: 25 (68%) | NA | 24 h: 19.95 ± 2.24; 48 h: 18.32 ± 1.77; 72 h: 21.05 ± 2.23; 96 h: 17.68 ± 1.40 | 21 (57) | NA | NA | ||
Soustiel19 | DC | NA | NA | NA | 15.2 ± 12.5 | NA | NA | 16.1 ± 12.7 | NA |
Medical therapy | NA | NA | NA | 12.4 ± 8.7 | NA | NA | 19.5 ± 11.3 | ||
Thomale17 | DC | Median: 4 IQR(2.5–4.5) | NA | Median: 4 (IQR: 3, 5) | 9.4 (range: 5.9–18.7) | NA | NA | Median: 20 (IQR: 4, 28.5) | NA |
Medical therapy | Median: 4 IQR (3–4.75) | NA | Median: 5 (IQR: 4, 5) | NA | NA | NA | Median: 6.5 (IQR: 2, 2.75) | ||
Cooper13 | DC | NA | Median: 3 (IQR 2–5) | NA | 14.4 ± 6.8 | 14 (19) | Median: 28 (IQR: 21, 62) | Median: 13 (IQR: 10, 18) | 27 |
Medical therapy | NA | Median: 4 (IQR 3–5) | NA | 19.1 ± 8.9 | 15 (18) | Median: 37 (IQR: 24, 44) | Median: 18 (IQR: 13, 24) | 14 | |
Nirula9 | DC | NA | NA | NA | 11.7 ± 11.8 | 63 (30) | 16.4 | 10.9 | NA |
Medical therapy | NA | NA | NA | 12.3 ± 13.1 | 59 (28) | 13.7 | 8.5 | ||
Hutchinson11 | DC | NA | Favorable: 86 (43%); Unfavorable: 115 (57%) | Favorable: 88 (45%); Unfavorable: 106 (55%) | Median: 14.5 (IQR: 1.7, 18) | 54 (26.8) | NA | Median: 15.0 | 33 |
Medical therapy | NA | Favorable: 65 (35%); Unfavorable: 123 (65%) | Favorable: 58 (32%); Unfavorable: 121 (68%) | Median: 17.1 (IQR: 4.2, 21.8) | 92 (48.9) | NA | Median: 20.8 | 18 |
